• Molecular NameRimexolone
  • SynonymNA
  • Weight370.533
  • Drugbank_IDDB00896
  • ACS_NO49697-38-3
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)3.81
  • pkaN/A
  • LogD (pH=7, predicted)3.81
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-4.75
  • LogSw (predicted, AB/LogsW2.0)0.0
  • Sw (mg/ml) (predicted, ACD/Labs)0.01
  • No.of HBond Donors1
  • No.of HBond Acceptors3
  • No.of Rotatable Bonds2
  • TPSA54.37
  • StatusFDA approved
  • Administrationoccular
  • PharmacologyA glucocorticoid steroid used to treat inflammation in the eye.
  • Absorption_valueN/A
  • Absorption (description)Systemically absorbed.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmUndergoes extensive metabolism. Following intravenous administration of radiolabeled rimexolone in rats, more than 80% of the dose was excreted in the feces as rimexolone and metabolites. Metabolites have been shown to be either less active than rimexolone or inactive in human glucocorticoid receptor binding assays.
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of overdose include retinal toxicity, glaucoma, and subcapsular cataract.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A